Investigators reported on the hepatitis C virus cascade of care throughout the first few years of a treatment-as-prevention program initiated in Iceland.
Researchers used real-world data to determine the impact of hepatic fibrosis on the effectiveness of sofosbuvir/velpatasvir treatment in an Asian population with hepatitis C virus infection.
Researchers studied the impact of current opioid agonist therapy on initiation of chronic hepatitis C virus treatment among a population of individuals who inject drugs.
Researchers attempted to determine if medications for opioid use disorder integrated with infectious disease measures can lead to better infectious disease outcomes.
The expanded approval was based on data from an open-label phase 2 trial that evaluated Epclusa in 41 patients 3 years to less than 6 years of age with chronic HCV infection.
Liver function changes were evaluated in HIV/HCV coinfected vs HCV monoinfected patients with cirrhosis who achieved HCV eradication following direct-acting antiviral therapy.
Researchers assessed the influence of direct-acting antivirals on gut microbiota by analyzing microbial diversity and composition in patients with hepatitis C virus infection with or without HIV.
Authors urge identifying people who have delayed or skipped health care services.
Investigators analyzed UK residents with HCV born in Africa to examine the effectiveness of direct-acting antivirals in individuals from lower- or middle-income countries.
The researchers wanted to collect data about the real-world effectiveness and safety of SOF/VEL in patients with chronic HCV infection and severe renal impairment.
